BioPharma Clinical Trials

Chipscreen's Chidamide Receives NMPA Approval for First-Line Treatment of DLBCL with MYC/BCL2 Expression

Shenzhen Chipscreen Biosciences announced that the company's lead innovative product Chidamide (Epidaza®) , an oral subtype-selective histone deacetyla...

 May 01, 2024 | News

Infinitopes Raises £12.8M to Expand Precision Immunomics™ for Five Additional Cancers

      - Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen disco...

 May 01, 2024 | News

AriBio Secures EMA Approval for Pivotal POLARIS-AD Alzheimer's Trial, Aligning with FDA and MHRA

AriBio Co., Ltd. (AriBio) announced authorisation from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a global, phase 3, early Alzh...

 April 30, 2024 | News

AstraZeneca's ENHERTU Shows Breakthrough in Treating HR-Positive, HER2-Low Breast Cancer in Latest Trial

Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statis...

 April 30, 2024 | News

Pfizer and Genmab's TIVDAK Wins FDA Full Approval for Cervical Cancer After Outperforming Chemotherapy in Key Trial

TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastat...

 April 30, 2024 | News

FDA Approves Ractigen Therapeutics' IND for Groundbreaking Bladder Cancer Therapy

Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration...

 April 29, 2024 | News

Onconic Therapeutics Gains South Korean Approval for Innovative GERD Treatment JAQBO

Onconic Therapeutics, a leading biotechnology company in Korea,  announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved JAQB...

 April 26, 2024 | News

Hyundai Bioscience Targets p53 Gene Mutations with Novel Niclosamide-Based Cancer Therapy

The only solution for intractable cancer caused by mutations in the p53 gene Planning clinical trials targeting cancer patients with no available treatm...

 April 26, 2024 | News

Naveris, Inc. Initiates Phase II Clinical Trial for HPV-Driven Head and Neck Cancer at MSKCC

-Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the launch of a Phase II clinical study in minimal ...

 April 25, 2024 | News

Hanmi Pharmaceutical Partners with MSD to Advance Immuno-Oncology Drug BH3120 in New Clinical Trial

Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesit...

 April 24, 2024 | News

Hyundai Bioscience Launches Clinical Trials for Innovative Niclosamide-Based Cancer Drug

Clinical trials of Niclosamide-based oral metabolic anticancer drug to commence for patients with difficult-to-treat cancers such as triple-negative...

 April 23, 2024 | News

Kintor Pharma Advances to Phase III with GT20029, Pioneering Topical Treatment for Male Androgenetic Alopecia

Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological th...

 April 22, 2024 | News

GenFleet Therapeutics Secures FDA Approval for Pioneering Phase III KRAS G12C Inhibitor Trial in Colorectal Cancer

GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Adm...

 April 22, 2024 | News

Hyundai Bioscience to Conduct Global Clinical Trials for Groundbreaking Dengue Treatment

Hyundai Bioscience CEO Oh Sang-gi,  announced its plan to launch global clinical trials for a revolutionary treatment targeting all four serotypes of ...

 April 22, 2024 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close